Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxia… Read more
Yipinhong Pharmaceutical Co Ltd Class A (300723) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.73 Billion CNY
Based on the latest financial reports, Yipinhong Pharmaceutical Co Ltd Class A (300723) has total liabilities worth CN¥2.73 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yipinhong Pharmaceutical Co Ltd Class A - Total Liabilities Trend (2013–2024)
This chart illustrates how Yipinhong Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yipinhong Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Yipinhong Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xinhuanet Co Ltd
SHG:603888
|
China | CN¥1.25 Billion |
|
North Huajin Chemical Industries Co Ltd
SHE:000059
|
China | CN¥13.74 Billion |
|
Modern Times Group Mtg AB
ST:MTG-B
|
Sweden | Skr8.67 Billion |
|
Tsakos Energy Navigation Ltd
NYSE:TEN
|
USA | $2.06 Billion |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥6.21 Billion |
|
John B Sanfilippo & Son Inc
NASDAQ:JBSS
|
USA | $247.60 Million |
|
American Public Education Inc
NASDAQ:APEI
|
USA | $245.96 Million |
|
Zehnder
SW:ZEHN
|
Switzerland | CHF189.35 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yipinhong Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yipinhong Pharmaceutical Co Ltd Class A (2013–2024)
The table below shows the annual total liabilities of Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.47 Billion | +36.56% |
| 2023-12-31 | CN¥1.81 Billion | -6.48% |
| 2022-12-31 | CN¥1.93 Billion | +14.63% |
| 2021-12-31 | CN¥1.69 Billion | +159.33% |
| 2020-12-31 | CN¥650.14 Million | +43.14% |
| 2019-12-31 | CN¥454.20 Million | -5.70% |
| 2018-12-31 | CN¥481.67 Million | +28.98% |
| 2017-12-31 | CN¥373.45 Million | -10.19% |
| 2016-12-31 | CN¥415.82 Million | -3.28% |
| 2015-12-31 | CN¥429.90 Million | -29.09% |
| 2014-12-31 | CN¥606.28 Million | +168.67% |
| 2013-12-31 | CN¥225.66 Million | -- |